Navigation Links
GlycoMeds Discovery Yields Early Warning Test for Cancer
Date:2/4/2009

PHOENIX, Feb. 4 /PRNewswire/ -- Cancer is the second leading cause of death with over 6 million new cases worldwide each year. In the U.S. alone, one million new cases of cancer are diagnosed annually, and half a million Americans lose their battle with the disease every year. Now, following years of research, GlycoMeds (http://www.cancer-test-kits.com) has released the first early detection system for whole-body cancers.

What was needed was a way to detect it in the early stages when it's easiest to treat. The medical establishment has long sought just such a tool -- a reliable, simple test that catches cancer in its early stages. While a few companies have designed tests for specific cancers, those tests require the cancer to be present. What's more, these tests are limited to only a few specific types of cancer.

In contrast, the GlycoMeds patent-pending Cancer Test (http://www.cancer-test-kits.com/articlesCancerMarketTest.htm) is a broad-scope test that detects conditions within the body that allow cancer cell growth prior to cancer cells being active. Employing a test process that produces consistent measurements of the chemical composition of a person's saliva, GlycoMeds' Cancer Test Kit is an inexpensive, at-home test that can alert the user to the presence of conditions within their body that are conducive to the growth of 74% of all cancers (including breast, lung, kidney, colon, liver, bone and brain cancer). The Cancer Test Kit does not measure pH.

"The new Cancer Test is not keyed for any specific cancer," explained Dr. Roger Brown, CEO of GlycoMeds. "The test is more sensitive to whole-body type of cancers rather than small, localized malignant tumors which don't generally disrupt the body's entire system."

The GlycoMeds Cancer Test works because most cancer cells live in a narrow pH range within the body. As long as the body's system pH is outside that range, most cancer cells cannot survive. The GlycoMeds test measures the changes in a person's fluidic system once a day for three days, averages those changes, and compares them to the changes a healthy person's fluidic system would undergo. The measurement is then equated to a condition level on a scale of 0 to 7, where 0 is healthy -- no conditions conducive to the growth of whole-body cancer cells -- and 7 has a prognosis of death.

If the level number reveals an active possibility of cancer (levels 4, 5 or 6), the person taking the test is advised to make an appointment with his or her doctor for further evaluation. But if the test shows cancer is not imminent (levels 1, 2 or 3), the person taking the test can take corrective action to bring his or her system back to normal, thus inhibiting cancer cell growth.

GlycoMeds is now seeking a partner to license and market their Cancer Test Kit, which has not yet been presented to the FDA for comment. To learn more, visit http://www.cancer-test-kits.com/articlesCancerMarketTest.htm.

    Contact:

    Roger Brown, Ph.D.
    GlycoMeds
    602-441-4225
    rbrown@vreh.com
   http://www.cancer-test-kits.com/contactUs.htm

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE GlycoMeds
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Discovery of sugar sensor in intestine could benefit diabetes
2. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
3. Stem cell research produces a key discovery for Fragile X Syndrome
4. Welch Foundation gives $1.6 million for drug discovery research
5. New discovery leaves blood-doping athletes scratching their heads
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. New discovery leaves blood-doping athletes scratching their heads
8. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
9. Discovery supports theory of Alzheimers disease as form of diabetes
10. Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits
11. New discovery may improve treatment of one of the worlds leading causes of blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: